Neoadjuvant treatment for resectable pancreatic adenocarcinoma

Table 1 Selected published neoadjuvant phase II trials in resectable pancreatic adenocarcinoma between 2006-2015

Trial/reference published year	Trial phase/patient number	Treatment regimen	Primary endpoint	Result
NCT00335543/2015[63]	II, randomized/66 (254 planned)	Upfront surgery vs chemoradiation with gemcitabine/cisplatin and radiotherapy of 55.8 Gy	Median survival	Median survival: 14.4 mo vs 17.4 mo (P = 0.96). Overall R0: 48% vs 52% (P = 0.81)
NCT00536874/2014[64]	II/38	Gemcitabine and oxaliplatin	18-mo overall survival	18-mo overall survival: 63%. Median overall survival: 27.2 mo. Resection rate was 71%, and 74% of resection was R0
NCT00490360/2008[20,65]	II/28	Gemcitabine and cisplatin	Resectability rate ≥ 70%	Resection rate was 89%, and 80% of resection was R0. Overall survival was 26.5 mo
Evans et al[21]	II/86	Chemoradiation with gemcitabine and radiotherapy of 30 Gy (in 10 fractions) for pancreatic head cancer	Clinical outcome	Overall R0: 74%. Median overall survival was 22.7 mo with a 5-yr survival of 27% (36% in R0)
Varadhachary[22]	II/90	Gemcitabine and cisplatin followed by chemoradiation with gemcitabine and radiotherapy of 30 Gy for pancreatic head cancer	Clinical outcome	Overall R0 was 58%. Additional chemotherapy did not improve clinical outcome
Palmer et al[66]	II, randomized/50	Gemcitabine vs gemcitabine and cisplatin	Resection rate	Resection rate was 54%: 9 (38%) in the gemcitabine arm and 18 (70%) in the combination arm